Identifying and Treating Familial Hypercholesterolemia

Details & Video

Program Time: 30 minutes - includes presentation and interactivity
Accreditation-CME Credits: Accreditation for this activity has expired; however, Mainpro+ participants may earn certified credits by completing a Linking Learning Exercise.
Target Audience: General Practitioners
Program Preview
Click image above to play the program preview.
English Full Program
Stable CAD thumbnail

Overview & Objectives

Identifying and Treating Familial Hypercholesterolemia

Target Audience: General Practitioners.

By participating in this educational program, health care providers will be able to:
  1. Examine the prevalence and risk associated with FH
  2. Review the strategies to recognize potential FH patients
  3. Identify optimal treatment strategies for FH



Planning Committee & Faculty

Planning Committee & Faculty

Milan Gupta
Milan Gupta
MD, FRCPC, FCCS

Associate Clinical Professor of Medicine,
McMaster University
Medical Director
Canadian Collaborative Research Network
View disclosures

Brampton, ON
Jeffrey Habert
Jeffrey Habert
M.D., CMFC, FCMF

Assistant Professor,
University of Toronto,
Dept. of Family and Community Medicine
View disclosures

Toronto, Ontario
Daniel Ngui
Daniel Ngui
B. Sc., PT, M.D., FCMF

Clinical Associate Professor
University of British Columbia
Medical Director
Fraser Street Medical
View disclosures

Vancouver, BC
Marla Shapiro
Marla Shapiro
C.M., M.D.C.M., CMFC, M. Sc. S., FRCPC, FCMF, NCMP

Professor, University of Toronto
Department of Family and Community Medicine
University Health Network
North York General, Mount Sinai
View disclosures

Toronto, Ontario
Rob Hegele
Faculty
Rob Hegele
MD, FRCPC, FACP, FAHA, FCAHS, FCCS

Jacob J. Wolfe Distinguished Medical Research Chair in Human Gene Function
Martha G. Blackburn Chair in Cardiovascular Research
Director, London Regional Genomics Centre
Scientist, Molecular Medicine, Robarts Research Institute
Distinguished University Professor, Departments of Medicine (Division of Endocrinology) and Biochemistry, Western University
View disclosures

London, Ontario

Agenda

Agenda

Program ChapterDuration
(Min:Sec)
Introduction2:02
Patient case5:34
Prevalence of FH4:39
Associated CV risk4:03
Identifying potential FH patient2:29
Treatment strategies4:31
Practical considerations and summary2:08


Sponsorship

CCRN sm

This program has been developed by the Canadian Collaborative Research Network, a not-for-profit physician organization, and is supported through an educational grant received from:

Amgen Canada

Links & Resources

Links & Resources:

  • Yuan et al. CMAJ 2006; 174:1124-9
  • Adapted from Nordestgaard BG et al. Eur Heart J 2013;34:3478-90a
  • Adapted from Austin MA et al. Am J Epidemiol 2004;160:421-9; Genest J et al. Can J Cardiol 2014;30:1471-81
  • Ruel, I et al. in review
  • Genest J. et al. Can J Cardiol. 2014; 30:1471-81
  • Defesche JC et al. Nat. Rev. Dis. Primers 2017 doi:10.1038/nrdp.2017.93
  • Adapted from Kastelein, JJP et al. As presented during ESC Congress 2015, Abstract 5772.
  • Raal F et al. Lancet 2015;385:331-40